Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old (any gender)
- People whose cancer cells have tested positive for a protein called CD123, detected through a blood/cell flow test
- People diagnosed with either relapsed/refractory AML (a type of blood cancer that has come back or stopped responding to treatment) or BPDCN (a rare blood cancer) that is CD123 positive, meeting specific disease criteria (confirm with trial site for exact details)
- People expected to live for more than 12 weeks
- People who are reasonably functional day-to-day, rated 0–2 on a standard medical scale called the ECOG scale (meaning able to carry out at least some daily activities)
- People without serious mental health disorders
- People whose heart is working well, with a heart pumping strength of at least 50% on an echo scan and no major abnormalities on a heart tracing (ECG)
- People whose kidneys are functioning within an acceptable range (confirm with trial site)
- People whose liver is functioning within an acceptable range (confirm with trial site)
- People with blood oxygen levels above 92%
- People (or their legal guardian) who are willing to sign a consent form confirming they understand and agree to take part in the study
Who may not be able to join:
- People who received chemotherapy, targeted therapy, or another experimental treatment within the past 14 days (or within 5 half-lives of the drug, whichever is shorter), unless disease worsening has been confirmed during that treatment
- People who had a stroke or seizure within the 6 months before signing the consent form
- People with an active or uncontrolled infection requiring ongoing treatment within 1 week before the screening visit
- People with moderate to severe heart failure (classified as NYHA Stage III or IV)
- People who had a heart attack or certain heart surgery within 6 months before joining
- People with a significant history of irregular heart rhythms or unexplained fainting (not caused by dehydration or a common fainting reflex)
- People with a history of severe non-ischemic heart muscle disease
- People with active hepatitis B infection
- People with active autoimmune disease who require long-term immune-suppressing medication
- People with another active cancer, except for certain fully treated early-stage cancers (such as some skin cancers, early cervical cancer, localised prostate cancer, or early breast cancer after surgery — confirm with trial site)
- People who received a live attenuated vaccine within 4 weeks before screening
- Women who are pregnant or breastfeeding
- People of any gender who plan to have children within 1 year of receiving the CAR T cell treatment used in this trial
- People who the research team considers unsuitable for other reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jia Wei, M.D, Shanxi Bethune Hospital
Phone: 13986102084
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety of CAR-NK cell preparations in the treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm[Safety and Tolerability]; To evaluate the efficacy of CAR-NK cell preparations in the treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm[Effectiveness]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.